BVB Medicine January 2020

From 1 February 2020, it is HSE policy that all adult patients who are commencing treatment with adalimumab or etanercept should be prescribed a best-value biological (BVB) medicine. Further information in relation to this, including a letter from the Medicines Management Programme to prescribers, is located in the Related Files section below: 

Clinical Design and Innovation